Comparative Pharmacology
Head-to-head clinical analysis: CRYSELLE versus FALMINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSELLE versus FALMINA.
CRYSELLE vs FALMINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cryselle is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin release, primarily through estrogenic and progestogenic effects on the hypothalamic-pituitary axis. It also increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo.
FALMINA (fictitious drug): 500 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 16-36 h), with clinical significance for once-daily dosing.
Terminal elimination half-life 12-15 hours; in severe renal impairment (CrCl <30 mL/min) extends to 30-40 hours, requiring dose adjustment.
Renal (50% as metabolites, 20% unchanged), fecal (30%), with enterohepatic recirculation.
Primarily renal (85% unchanged drug, 10% as glucuronide conjugate); biliary/fecal 5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive